Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F14%3A00431314" target="_blank" >RIV/67985823:_____/14:00431314 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1007/s10557-014-6530-0" target="_blank" >http://dx.doi.org/10.1007/s10557-014-6530-0</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10557-014-6530-0" target="_blank" >10.1007/s10557-014-6530-0</a>

Result language
angličtina
Original language name
Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat
Original language description
We tested the hypothesis that a novel angiotensin II receptor blocker, azilsartan medoxomil (AZL-M), will prevent renal and cardiovascular injury in the spontaneously hypertensive obese rat (SHROB), a model of cardiometabolic syndrome. AZL-M demonstratedstrong kidney protective effects with lower albuminuria and nephrinuria along with reduced tubular cast formation and glomerular injury. AZL-M treatment also improved left ventricular heart function, attenuated development of left ventricular hypertrophy, and reduced cardiac fibrosis in SHROB. These findings demonstrate kidney and heart protective effects of AZL-M in SHROB
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Project
<a href="/en/project/GA13-10267S" target="_blank" >GA13-10267S: Cardiac ischemic tolerance of spontaneously hypertensive rats: involvement of mitochondrial genome</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)